Correction: TRAIL resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer (PLoS ONE (2019) 9:6 (e99067) DOI: 10.1371/journal.pone.0099067);Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Wang, Haiji ^a,b   Xu, Chunyuan ^a,c   Kong, Xiaoli ^a   Li, Xiaoyan ^a   Kong, Xiangnan ^a   Wang, Yu ^a   Ding, Xia ^a   Yang, Qifeng ^a  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^c QINGDAO MUNICIPAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 221; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; MICRORNA; MIRN122 MICRORNA, HUMAN; PTEN PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL MIGRATION; CELL STRAIN; CELL STRAIN MDA MB 231; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ENZYME REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; PROTEIN TARGETING; TUMOR INVASION; UPREGULATION; APOPTOSIS; BREAST; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; PTEN PHOSPHOHYDROLASE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84902603060     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0214433     Document Type: Erratum

References (44)

1. Benson JR, Jatoi I (2012) The global breast cancer burden. Future Oncol 8: 697-702.
2. Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, et al. (2012) The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 36: 237-248.
3. Griffith TS, Lynch DH (1998) TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10: 559-563. (Pubitemid 28479189)
4. Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, et al. (2008) A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 14: 3450-3455.
5. de Jong S, Timmer T, Heijenbrok FJ and de Vries EG (2001) Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev 20: 51-56. (Pubitemid 34074678)
6. Lagadec C, Adriaenssens E, Toillon RA, Chopin V, Romon R, et al. (2008) Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells. Oncogene 27: 1472-1477. (Pubitemid 351317455)
7. Tomek S, Horak P, Pribill I, Haller G, Rossler M, et al. (2004) Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecol Oncol 94: 107-114. (Pubitemid 38950505)
8. Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, et al. (2010) Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther 10: 885-892.
9. Ding J, Polier G, Kohler R, Giaisi M, Krammer PH, et al. (2012) Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression. J Biol Chem 287: 641-649.
10. Voelkel-Johnson C, King DL, Norris JS (2002) Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 9: 164-172. (Pubitemid 34141919)
11. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, et al. (2009) TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 113: 217-230.
12. Srivastava RK, Kurzrock R, Shankar S (2010) MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 9: 3254-3266.
13. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, et al. (1999) Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59: 2747-2753. (Pubitemid 29269125)
14. Shin EC, Seong YR, Kim CH, Kim H, Ahn YS, et al. (2002) Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med 34: 114-122. (Pubitemid 34664327)
15. Zhuang H, Jiang W, Zhang X, Qiu F, Gan Z, et al. (2012) Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions. J Mol Med (Berl).
16. Falschlehner C, Emmerich CH, Gerlach B, Walczak H (2007) TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39: 1462-1475. (Pubitemid 47031030)
17. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, et al. (2003) TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22: 3842-3852. (Pubitemid 36819657)
18. Bossen C, Tardivel A, Willen L, Fletcher CA, Perroud M, et al. (2011) Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses. Eur J Immunol 41: 787-797.
19. Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, et al. (2004) Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 279: 40044-40052. (Pubitemid 39258279)
20. Schneider P (2000) Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins. Methods Enzymol 322: 325-345.
21. Germano S, O'Driscoll L (2009) Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine. Curr Cancer Drug Targets 9: 398-418.
22. Rahman M, Pumphrey JG, Lipkowitz S (2009) The TRAIL to targeted therapy of breast cancer. Adv Cancer Res 103: 43-73.
23. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
24. Zhang AL, Wang QS, Zhong YH, Chen G, Xi L, et al. (2005) [Effect of transcriptional factor snail on epithelial-mesenchymal transition and tumor metastasis]. Ai Zheng 24: 1301-1305.
25. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, et al. (2007) Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31: 277-283.
26. Chen X, Lingala S, Khoobyari S, Nolta J, Zern MA, et al. (2011) Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol 55: 838-845.
27. Sansal I, Sellers WR (2004) The biology and clinical relevance of the PTEN tumor suppressor pathway. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 22: 2954-2963.
28. Waite KA, Eng C (2002) Protean PTEN: form and function. American journal of human genetics 70: 829-844. (Pubitemid 34259300)
29. Tanic N, Milovanovic Z, Tanic N, Dzodic R, Juranic Z, et al. (2012) The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients. Cancer Biol Ther 13: 1165-1174.
30. Lai D, Visser-Grieve S, Yang X (2012) Tumour suppressor genes in chemotherapeutic drug response. Bioscience reports 32: 361-374.
31. Xu J, Zhou JY, Wei WZ, Wu GS (2010) Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 5: e10226.
32. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, et al. (2012) Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 72: 1878-1889.
33. Bonavida B, Baritaki S (2011) The novel role of Yin Yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NF-kappaB/Snail/YY1/RKIP/PTEN Circuitry. Critical reviews in oncogenesis 16: 211-226.
34. Han M, Liu M, Wang Y, Chen X, Xu J, et al. (2012) Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One 7: e39520.
35. Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, et al. (2010) MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer 10: 367.
36. Zaman MS, Thamminana S, Shahryari V, Chiyomaru T, Deng G, et al. (2012) Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer. PLoS One 7: e50203.
37. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, et al. (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 425-433. (Pubitemid 351380068)
38. Jackson AL, Levin AA (2012) Developing microRNA therapeutics: approaching the unique complexities. Nucleic Acid Ther 22: 213-225.
39. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350-355.
40. Lovat F, Valeri N, Croce CM (2011) MicroRNAs in the pathogenesis of cancer. Semin Oncol 38: 724-733.
41. Ye X, Bai W, Zhu H, Zhang X, Chen Y, et al. (2013) MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. BMB reports.
42. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, et al. (2011) miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci Signal 4: pt5.
43. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, et al. (2009) miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16: 498-509.
44. Acunzo M, Visone R, Romano G, Veronese A, Lovat F, et al. (2012) miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene 31: 634-642.